Home › Compare › WLFDY vs ABBV
WLFDY yields 67.73% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 6
Combined, WLFDY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WLFDY + ABBV for your $10,000?
Wolford Aktiengesellschaft produces and markets legwear, ready-to-wear garments, lingerie, beachwear, and accessories in Austria, Germany, France, the United Kingdom, Ireland, rest of Europe, North America, and Asia/Oceania. Its legwear products include pantyhose, tights, leggings, stay-ups, knee-highs, and socks; and lingerie comprises bras, briefs, bodies, garter belts, and slips. The company's ready-to-wear products include sweaters, dresses, skirts, and trousers; accessories comprise scarves and belts; and beachwear products include swimsuits and bikinis. It also offers bodysuits and close-fitting knitwear, such as tops and shirts. The company sells its products through boutiques, concession shop-in-shops, online business, factory outlets, department stores, specialist retail stores, and private label. As of December 31, 2021, it had 229 monobrand points of sales, which include 101 boutiques, 48 concession shop-in-shops, and 18 factory outlets owned by the company; 62 partners-operated boutiques; and approximately 2,500 other distribution partners. The company was founded in 1950 and is headquartered in Bregenz, Austria. Wolford Aktiengesellschaft is a subsidiary of Fosun Industrial Holdings Limited.
Full WLFDY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.